Effect of verapamil in infants with paroxysmal supraventricular tachycardia. 1979

J Soler-Soler, and J Sagristá-Sauleda, and A Cabrera, and J Sauleda-Parés, and J Iglesias-Berengué, and G Permanyer-Miralda, and J Roca-Llop

Twenty-nine consecutive spontaneous attacks of paroxysmal supraventricular tachycardia (PSVT) in 14 infants (mean age 4.4 months) were treated with verapamil. No infant had associated heart disease. Verapamil 1-2 mg i.v was administered over 30 seconds. The dosage varied according to the weight of the infant. Within 60 seconds sinus rhythm was obtained in 28 instances (96.5%). No significant complications were observed. The high effectiveness, rapid action and lack of undesirable side effects observed in this series suggest that verapamil is the drug of choice in the treatment of PSVT in infants without underlying heart disease.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013614 Tachycardia, Paroxysmal Abnormally rapid heartbeats with sudden onset and cessation. Paroxysmal Reciprocal Tachycardia,Paroxysmal Reciprocal Tachycardias,Paroxysmal Tachycardia,Paroxysmal Tachycardias,Reciprocal Tachycardia, Paroxysmal,Reciprocal Tachycardias, Paroxysmal,Tachycardia, Paroxysmal Reciprocal,Tachycardias, Paroxysmal,Tachycardias, Paroxysmal Reciprocal
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014700 Verapamil A calcium channel blocker that is a class IV anti-arrhythmia agent. Iproveratril,Calan,Cordilox,Dexverapamil,Falicard,Finoptin,Isoptin,Isoptine,Izoptin,Lekoptin,Verapamil Hydrochloride,Hydrochloride, Verapamil

Related Publications

J Soler-Soler, and J Sagristá-Sauleda, and A Cabrera, and J Sauleda-Parés, and J Iglesias-Berengué, and G Permanyer-Miralda, and J Roca-Llop
January 1979, Indian heart journal,
J Soler-Soler, and J Sagristá-Sauleda, and A Cabrera, and J Sauleda-Parés, and J Iglesias-Berengué, and G Permanyer-Miralda, and J Roca-Llop
February 1981, The Journal of pediatrics,
J Soler-Soler, and J Sagristá-Sauleda, and A Cabrera, and J Sauleda-Parés, and J Iglesias-Berengué, and G Permanyer-Miralda, and J Roca-Llop
April 1959, Medical times,
J Soler-Soler, and J Sagristá-Sauleda, and A Cabrera, and J Sauleda-Parés, and J Iglesias-Berengué, and G Permanyer-Miralda, and J Roca-Llop
June 1965, Revue medicale de Liege,
J Soler-Soler, and J Sagristá-Sauleda, and A Cabrera, and J Sauleda-Parés, and J Iglesias-Berengué, and G Permanyer-Miralda, and J Roca-Llop
July 1974, Postgraduate medical journal,
J Soler-Soler, and J Sagristá-Sauleda, and A Cabrera, and J Sauleda-Parés, and J Iglesias-Berengué, and G Permanyer-Miralda, and J Roca-Llop
November 1984, Clinical cardiology,
J Soler-Soler, and J Sagristá-Sauleda, and A Cabrera, and J Sauleda-Parés, and J Iglesias-Berengué, and G Permanyer-Miralda, and J Roca-Llop
January 1984, Vutreshni bolesti,
J Soler-Soler, and J Sagristá-Sauleda, and A Cabrera, and J Sauleda-Parés, and J Iglesias-Berengué, and G Permanyer-Miralda, and J Roca-Llop
May 1984, Critical care medicine,
J Soler-Soler, and J Sagristá-Sauleda, and A Cabrera, and J Sauleda-Parés, and J Iglesias-Berengué, and G Permanyer-Miralda, and J Roca-Llop
March 1976, European journal of cardiology,
J Soler-Soler, and J Sagristá-Sauleda, and A Cabrera, and J Sauleda-Parés, and J Iglesias-Berengué, and G Permanyer-Miralda, and J Roca-Llop
May 1991, Annals of emergency medicine,
Copied contents to your clipboard!